Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03004248 · ClinicalTrials.gov registry record · Phase 3
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
A Phase 3 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,691
- Enrollment target
NCT03004248 is a Phase 3 study that has completed, run by Revance Therapeutics. The registered enrollment target is 2,691 participants.
The verdict
NCT03004248, a Phase 3 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,691 participants
- Enrollment target
Study Summary
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
Interventions
- BIOLOGICAL Botulinum Toxins, Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,691 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2018-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03004248
The ClinicalTrials.gov registry entry for NCT03004248 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,691 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxins, Type A is the first listed.
NCT03004248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03004248 about?
NCT03004248 is a clinical study titled "Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines". This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
What is the current status of trial NCT03004248?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,691 participants. The study started on 2016-12-09. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT03004248?
The interventions under investigation include: Botulinum Toxins, Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03004248?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.